Sale of the Company's entire minority investment in Diagnosis S.A. (78,750 shares) to purchasers including Mr. Irani.
| Officer | Age | In this role | Joined | 2026 pay | Source |
|---|---|---|---|---|---|
|
Zackary Irani
Also a director
Chief Executive Officer and Director
|
60 |
Since 1997
29 years
|
Not stated | $285,450 | |
|
Allen Barbieri
Also a director
Executive Vice-Chairperson of the Board and Corporate Secretary
|
68 |
Since 2020
6 years
|
Not stated | $165,400 | |
|
Xiaoxuan (“Jenny”) Qu
See Remarks
Title from the Form 3 dated Aug 27, 2026
|
33 | Not stated | 2023 | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Sale of the Company's entire minority investment in Diagnosis S.A. (78,750 shares) to purchasers including Mr. Irani.
Secured promissory term note issued by the Company to Mr. Irani bearing 8% interest and maturing May 29, 2027, secured by the Diagnosis S.A. shares.
Purchased 31,250 shares in the August 2026 Private Placement at $1.60 per share.
Purchased 20,000 shares in the August 2026 Private Placement at $1.60 per share.
Purchased 6,250 shares in the August 2026 Private Placement at $1.60 per share.
Purchased 31,250 shares in the August 2026 Private Placement at $1.60 per share.
Purchased 10,000 shares in the August 2026 Private Placement at $1.60 per share.
Loading...